



Homoplasmic mitochondrial tRNA Pro mutation causing exercise-induced muscle swelling and fatigue

Karine Auré, Guillemette Fayet, Ivan Chicherin, Benoit Rucheton, Sandrine Filaut, Anne-Marie Heckel, Julie Eichler, Florence Caillon, Yann Pereon, Nina Entelis, et al.

► To cite this version:

Karine Auré, Guillemette Fayet, Ivan Chicherin, Benoit Rucheton, Sandrine Filaut, et al.. Homoplasmic mitochondrial tRNA Pro mutation causing exercise-induced muscle swelling and fatigue. *Neurology Genetics*, 2020, 6 (4), pp.e480. <10.1212/NXG.0000000000000480>. <hal-02900529>

HAL Id: hal-02900529

<https://hal.science/hal-02900529v1>

Submitted on 16 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Homoplasmic mitochondrial tRNA^{Pro} mutation causing exercise-induced muscle swelling and fatigue

Karine Auré, MD, PhD, Guillemette Fayet, MD, PhD, Ivan Chicherin, PhD, Benoit Rucheton, PharmD, Sandrine Filaut, Anne-Marie Heckel, Julie Eichler, MSc, Florence Caillon, MD, Yann Péréon, MD, PhD, Nina Entelis, PhD, Ivan Tarassov, PhD, and Anne Lombès, MD, PhD

Neurol Genet 2020;6:e480. doi:10.1212/NXG.0000000000000480

Correspondence

Dr. Lombès
anne.lombes@inserm.fr
or Dr. Tarassov
i.tarassov@unistra.fr

Abstract

Objective

To demonstrate the causal role in disease of the *MT-TP* m.15992A>T mutation observed in patients from 5 independent families.

Methods

Lactate measurement, muscle histology, and mitochondrial activities in patients; PCR-based analyses of the size, amount, and sequence of muscle mitochondrial DNA (mtDNA) and proportion of the mutation; respiration, mitochondrial activities, proteins, translation, transfer RNA (tRNA) levels, and base modification state in skin fibroblasts and cybrids; and reactive oxygen species production, proliferation in the absence of glucose, and plasma membrane potential in cybrids.

Results

All patients presented with severe exercise intolerance and hyperlactatemia. They were associated with prominent exercise-induced muscle swelling, conspicuous in masseter muscles (2 families), and/or with congenital cataract (2 families). MRI confirmed exercise-induced muscle edema. Muscle disclosed severe combined respiratory defect. Muscle mtDNA had normal size and amount. Its sequence was almost identical in all patients, defining the haplotype as J1c10, and sharing 31 variants, only 1 of which, *MT-TP* m.15992A>T, was likely pathogenic. The mutation was homoplasmic in all tissues and family members. Fibroblasts and cybrids with homoplasmic mutation had defective respiration, low complex III activity, and decreased tRNA^{Pro} amount. Their respiratory complexes amount and tRNA^{Pro} aminoacylation appeared normal. Low proliferation in the absence of glucose demonstrated the relevance of the defects on cybrid biology while abnormal loss of cell volume when faced to plasma membrane depolarization provided a link to the muscle edema observed in patients.

Conclusions

The homoplasmic *MT-TP* m.15992A>T mutation in the J1c10 haplotype causes exercise-induced muscle swelling and fatigue.

From the Inserm U1016 Institut Cochin (K.A., B.R., A.L.), INSERM, Paris; Department of Neurophysiology (K.A.), Foch Hospital, Suresnes; Centre de Référence Maladies Neuro-musculaires Hôtel-Dieu AOC (G.F., Y.P.), CHU Nantes; CNRS UMR 7156 GMGM (I.C., A.-M.H., J.E., N.E., I.T.), University of Strasbourg; Service de Biochimie Métabolique CHU Pitié-Salpêtrière (B.R., S.F.), AP-HP, Paris; Service de Radiologie et Imagerie Médicale Hôtel-Dieu (F.C.), CHU Nantes; CNRS UMR 8104 (A.L.); Université Paris-Descartes-Paris5 (A.L.), Paris, France; and Present Address: M.V. Lomonossov State University (I.C.), Moscow, Russia.

Go to [Neurology.org/NG](https://www.neurology.org/NG) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

mtDNA = mitochondrial DNA; **mt-tRNA** = mitochondrial transfer RNA; **STIR** = short-tau inversion recovery; **TMRE** = tetramethylrhodamine ethyl ester.

Mitochondrial diseases, due to oxidative phosphorylation defects, represent an extraordinary diagnostic challenge because of their diversity. The hundreds of genes involved, located on either the mitochondrial or the nuclear DNA,¹ or the frequent heteroplasmy of mitochondrial DNA (mtDNA) mutations, i.e., coexistence of wild-type and mutant mtDNA molecules,² likely explain part of that diversity. In addition, deleterious homoplasmic mtDNA mutations, i.e., mutations affecting all mtDNA molecules, cause diseases with incomplete penetrance and tissue-specific expression that disclose the complexity of nuclear-mitochondrial interaction.³ This was the case with mutations causing Leber hereditary optic neuropathy⁴ or deafness.⁵ It was particularly striking for the homoplasmic *MT-TI* m.4300A>G mutation whose expression pattern ranged from infantile cardiac failure with severe cardiac mitochondrial defect to apparent health.⁶ Initial identification of these deleterious homoplasmic mutations thus required either their recurrence with a characteristic phenotype⁴ or the demonstration of the mitochondrial defect in the clinically targeted organ.⁶

Among deleterious mtDNA mutations, point mutations affecting transfer RNA (tRNA) genes are common (see Mitomap at mitomap.org). Their identification relies on a pathogenicity scoring system using criteria from clinical investigations, database analysis, and functional studies.⁷ Among the functional studies, cybrids, i.e., cytoplasmic hybrids with the patient's mtDNA and the nuclear genome from immortal cells⁸ bring the possibility to demonstrate the mtDNA origin of the mitochondrial defect and are thus considered a gold standard for the pathogenicity assessment of mtDNA mutations.⁷ However, as expected with mutations causing tissue-specific expression impairment, these cells, being a surrogate tissue for the disease, often disclosed only a mild mitochondrial defect.^{9,10}

The impact of tRNA mutations depends on the minimal set of 22 mtDNA tRNAs using a nonuniversal genetic code and specific decoding rules for mitochondrial protein synthesis.¹¹ In particular, all the codons with any base in the third codon position encoding the same amino acid are recognized by only 1 tRNA that carries an unmodified U in the wobble position of the anticodon.¹²

We here report the homoplasmic mtDNA m.15992A>T mutation of the wobble position of tRNA^{Pro} in 5 families with severe exercise intolerance and combined respiratory chain defect in muscle. We demonstrate the mutation pathogenicity in cybrids by showing its association with respiratory defect, decreased tRNA^{Pro} steady state, and altered response to depolarization reminiscent of the exercise-induced ionic disturbances observed in patients.

Patients and methods

Patients

Patient 1 (III-10 in family 1 in figure 1) presented with swelling of the temporal and masseter muscles during feeding since the neonatal period. Exercise intolerance occurred during early childhood, never associated with rhabdomyolysis. At age 22 years, she sought medical advice for myalgia and exhaustion after walking 500 m, followed with nausea, vomiting, and headache if effort was continued. Physical examination was normal at rest. Lactatemia was 2.1 mM in the fasting state and high after nonischemic forearm exercise test.¹³

Patient 2 (III-13 in family 1) sought medical advice at age 14 years for clinical and biological signs similar to patient 1.

Patient 3 (II-2 in family 2) presented at age 14 years with fatigability and muscle pain after moderate exercise (1 km cycling). He also presented with bilateral cataract, which was present in his mother. His physical examination was normal apart from short stature (−2.5 SD). Lactatemia was 6 mM in the postprandial state and high after moderate effort.

Patient 4 (III-6 in family 3) complained of myalgia and fatigability since early childhood, with vomiting if effort was continued. Physical examination only disclosed short stature (−3 SD). Lactatemia was 6.3 mM in the fasting state and high after effort.

Patient 5 (III-5 in family 4) complained of myalgia and muscle fatigue since age 3 years. Vomiting and malaise after prolonged efforts started after age 6 years. At age 13 years, she could only walk 200 m. Lactatemia was high in the fasting state (3.3 mM) and after nonischemic forearm exercise test.¹³

Patient 6 (III-5 in family 5 in figure 1) presented with congenital cataract. Severe exercise intolerance occurred in childhood and was associated with masseter swelling. At age 38 years, she could only walk 500 m because of myalgia and muscular exhaustion. Lactatemia was normal in the fasting state but high after exercise.


Methods

Patients' investigations

All patients gave their written informed consent for their analyses for diagnostic investigations and for their use in clinical research and publication, according to our institutional ethics board. The study received approval from our Institutional Review Board.

Brain imaging used a 1.5 T General Electric MRI with a head and neck coil, including coronal and axial T1 and short-tau inversion recovery (STIR) sequences.

Figure 1 Family trees of the patients with the m.15992A>T mutation



Arrows indicate the proband in each family; stars = subjects with samples for molecular studies; white forms = subjects asymptomatic or without sufficient information; black forms = patients with severe exercise intolerance, i.e., disabling daily life; gray forms = moderate exercise intolerance, i.e., not disabling daily life but clearly experienced; striped forms = patients with isolated chewing-induced masseter swelling; question marks indicate unknown clinical status of the subject. In families 1 and 5, severe intolerance to exercise was constantly associated with chewing-induced masseters swelling, but the reverse was not true with several patients in family 5 presenting only chewing-induced masseters swelling.

Muscle fragments were immediately frozen and stored at -80°C until use. Standard procedures provided blood, buccal mucosa cells, urinary sediment, and cultured fibroblasts derived from a forearm skin biopsy (patients 1, 2, 3, and 4). Muscle histology followed standardized protocols.^{14,15}

Molecular biology

Extraction of DNA from muscle and fibroblasts used standard methods based on proteinase K and SDS digestion; it used QIAamp DNA Mini Kit extraction (Qiagen) for blood, cells from buccal mucosa, or urinary sediment. Extraction of RNA used the miRNeasy Mini Kit (Qiagen) or TRIzol (Thermo Fisher Scientific).

Long-range PCR screened for large-scale deletions, while quantitative PCR evaluated the mtDNA copy number.¹⁶ The Sanger method provided mtDNA sequence. Mispairing PCR restriction quantified heteroplasmy using the DdeI site created by the mutation. Primers are in table e-1, links.lww.com/NXG/A282.

Quantification of mitochondrial tRNAs used Northern blotting of 8% polyacrylamide 8 M urea (Tris-borate) gels on Hybond N+ membranes and T4 polynucleotide kinase—5'-end ^{32}P -labeled probes (table e-1, links.lww.com/NXG/A282).

A282). Radioactive signals were quantified using Typhoon Trio and ImageQuant software (GE Healthcare).


Acid-denaturing gel separation and Northern blot analyzed the tRNA aminoacylation state¹⁷ while [^{35}S]-methionine in vivo labeling in the presence of emetin, a specific inhibitor of cytosolic ribosomes, assessed mitochondrial translation¹⁸ and reverse transcription followed by PCR (RT-PCR) with extended oligonucleotides and sequencing with shorter primers (table e-1, links.lww.com/NXG/A282) searched for the presence of inosine at the wobble position of tRNA anticodon.¹⁹

Cell biology

Cytoplasmic hybrids (cybrids) were obtained from patients 1 and 4 fibroblasts.⁸

Cell respiration was analyzed in Oroboros high-resolution respirometer,²⁰ whereas mitochondrial activities in muscle and fibroblasts used standardized spectrophotometric protocols.²¹ Mitochondrial production of superoxide ion was assessed by flow cytometry using 5 μM MitoSOX Red (Invitrogen).²²

Mitochondrial pellet preparation and Western blot after blue native polyacrylamide gel electrophoresis were as described in



Coronal T1-weighted NMRI of the head of patient 6 (A and B) and her aunt (C and D); coronal STIR NMRI of patient 6 (E and F) and her aunt (G and H); images obtained at rest (A, C, E, and G) and 15 minutes after chewing a sandwich (B, D, F, and H). The measures show that after chewing, the diameter of temporal muscle increased by 22% in patient 6 (A vs B) and by 34% in her aunt who increased the diameter of her masseter muscle by 37% (C vs D). NMRI = nuclear magnetic resonance imaging; STIR = short-tau inversion recovery.

Ref. 23. Primary antibodies were polyclonal antibodies against the F₁ domain of bovine complex V, UQCRC2, MT-ND1, or MT-CO2 (respectively produced by Pr Joël Lunardi, Grenoble, by Dr Catherine Godinot, Lyon, or our group²⁴) or monoclonal antibodies against the respiratory complex II SDHA subunit SDHA (Abcam), incubated overnight at 0°–4°C. Secondary antibodies were peroxidase conjugated (Sigma-Aldrich) and visualized with Pierce™ ECL Western Blotting Substrate (Life Technologies). Quantification used volumes and basal adjustment with rolling ball by Fusion FX (Vilber Company).

To analyze cell proliferation, 3,000 cells per well were cultured in four 24-well plates and Dulbecco Modified Eagle Medium with 1 mM pyruvate and either 1 g/L glucose or 200 μM glutamine without glucose.²⁵ Cell numbering was performed, in triplicates for each condition, every 24 hours (T0, T24, T48, and T72 plates) using the neutral red method²⁶ and expressed as fold increase relative to T0.

To evaluate plasma membrane, 100,000 cybrid cells were incubated in 96-well plate with 7.5 μM tetramethylrhodamine ethyl ester (TMRE) and 5 μM verapamil, an inhibitor of the multidrug resistance-associated proteins. Because resting membrane potential essentially depends on K diffusion gradient, progressive increase of external K concentration (from 10 to 80 mM) induced progressive depolarization. Osmolarity was kept at 300 mOsm/L. After 120-minute incubation, fluorescence was quantified by the Accuri™ C6 flow cytometer.

Statistics

Normality evaluation used the Shapiro-Wilk test. Depending on the distribution of data, comparison between 2 groups used the Mann-Whitney or *t* test. Differences were considered significant when *p* < 0.05.

Data availability

Any data not published within the article will be shared, as anonymized data, by request from any qualified investigator.

Results

The chewing-induced masticatory muscle swelling was due to edema

Nuclear MRI of facial muscles analyzed the exercise-induced muscle swelling in 2 members of family 5. Chewing a sandwich during 15 minutes induced a 20%–30% increase in thickness of the temporal and masseter muscles of patient 6 (figure 2, A and B) and her aunt (II-5 in family 5) (figure 2, C and D). Mild adipose infiltration of the masseter and lateral pterygoid muscles was present in patient 6's aunt. Prolonged edema was indicated by hypersignal in STIR, fat-suppression images, in all masticatory muscles of patient 6 (figure 2, E and F), and in the masseter, temporal, and lateral pterygoid muscles of her aunt (figure 2, G and H).

Mitochondrial myopathy underlay the muscle symptoms

Muscle histology disclosed mild alterations in patients 2, 3, 4, and 5, including moderate lipodosis and increased subsarcolemmal

Table 1 Mitochondrial activities in the muscle of patients with homoplasmic m.15992A>T mutation

	P2	P3	P4	C1 (n = 200)	P5	P6	C2 (n = 140)
CI total	11^a	8^a	7^a	25 ± 7	17^a	21^a	48 ± 15
CI rot sens	0^a	6^a	0^a	22 ± 7	12^a	18^a	42 ± 14
CII	39	90	30	31 ± 8	77	136	62 ± 19
CIII total	80^a	26^a	23^a	124 ± 274	70^a	63^a	235 ± 64
CIII am sens	22^a	11^a	5^a	107 ± 26	6^a	23^a	160 ± 59
II + CIII	3^a	5^a	2^a	18 ± 7	14^a	13^a	50 ± 15
CIV	43 ^a	63 ^a	9 ^a	56 ± 17	109 ^a	89 ^a	199 ± 57
CS	314	1,005	248	153 ± 35	276	470	209 ± 64

Abbreviations: CI total = NADH ubiquinone oxidoreductase activity; CI rot sens = CI fraction sensitive to rotenone inhibition, i.e., specific respiratory complex I activity; CII = succinate ubiquinone oxidoreductase activity, i.e., respiratory complex II activity; CIII total = ubiquinol cytochrome c oxidoreductase activity; CIII am sens = CIII fraction sensitive to antimycin inhibition, i.e., specific respiratory complex III activity; CIV = cytochrome c oxidase activity, i.e., respiratory complex IV activity; CS = activity of citrate synthase, a Krebs cycle enzyme considered as representing the mitochondrial mass; n = number of different controls analyzed in each series.

Activities in bold font indicate values below the 10th centile of control values; activities in italics font indicate values above the 90th centile of control values. ^a After the respiratory activities indicate values below the 10th centile of control values after their normalization to citrate synthase activity. P2, P3, P4, P5, and P6 = results obtained in the muscle biopsy from patients 2, 3, 4, 5, and 6; C1, C2 = successive control series due to the change of spectrophotometric assays in 2009.²¹

mitochondria (figure e-1A, links.lww.com/NXG/A279). It was considered normal for patient 6.

Spectrophotometric assays of the respiratory chain revealed severe combined defect of respiratory complexes I, III, and IV with increased citrate synthase in the muscle biopsies from all probands (table 1). Respiratory complex II, the only complex without mtDNA-encoded subunit, was either normal or elevated.

All patients shared the same homoplasmic *MT-TP* m.15992A>T mutation

Long-range PCR excluded the presence of large size rearrangement, whereas quantitative PCR ruled out depletion. Sequencing of the whole mtDNA sequence revealed that all patients had the same mtDNA, sharing 31 of 32 variants (table e-2, links.lww.com/NXG/A283). Thirty-one of these 32 variants were highly likely polymorphisms: 28 reported at least 1,462 times in GenBank database, a *MT-RNR1* variant reported 37 times in different ethnic backgrounds, and 2 synonymous mutations (*MTND2* c.5024C>T and *MT-CO1* m.7028C>T) (mitomap.org). These polymorphisms defined the mtDNA haplotype as J1c10 for all the families. The last variant, common to all patients, was the m.15992A>T mutation in the *MT-TP* gene. Several criteria indicated its potential pathogenicity: (1) it was reported only once in more than 49,000 GenBank full-length mtDNA sequences; (2) it modified the strictly phylogenetically conserved wobble base in the tRNA anticodon (see MitotRNAdb/Mamit-tRNA website at mttrna.bioinf.uni-leipzig.de); and (3) alteration of the wobble position in mt-tRNA anticodon is a major deleterious factor in several mt-tRNA confirmed mutations.²⁷

The mutation appeared homoplasmic (figure 3) with PCR restriction in the DNA samples from muscle of all the

probands, from blood of all patients marked with a star in figure 1, and from urinary sediment and buccal cells of patients 1 and 2, their mother, and grandmother.


Transfer of the m.15992A>T mutation into cybrids demonstrated its deleterious potential on OXPHOS activities

Fibroblasts derived from a skin biopsy of patients 1, 2, 3, and 4 had 100% mutation (figure 3). They disclosed a mild but significant decrease of their basal respiration and respiration linked to adenosine triphosphate (ATP) production (figure 4A). Citrate synthase activity was significantly increased (figure 4B). Complexes I, III, IV, and V appeared decreased, reaching significance for complex III after normalization to citrate synthase (figure 4, B and C).

Cybrid clones, derived from patient 2 and patient 4 fibroblasts, had homoplasmic m.15992A>T mutation (figure 3). They showed decreased respiration, either basal, linked to ATP production, or maximal (figure 4A). As in fibroblasts, cybrids had decreased activity for all the mtDNA-depending complexes, reaching significance for respiratory complex III (figure 4, B and C). The amount of the respiratory complexes appeared normal when analyzed by Western blot after blue native polyacrylamide gel electrophoresis (figure e-1B, links.lww.com/NXG/A279).

Mutant cells disclosed significantly slower proliferation than control cells in the absence of glucose, whereas their proliferation rate was identical in its presence (figure 5A). The mild oxidative phosphorylation pathway (OXPHOS) defect was therefore relevant, affecting the cell proliferation capacity in a medium without glucose.^{25,28,29} It had no apparent impact on the mitochondrial production of superoxide ion, which was similar in mutant and control cybrids in the basal state (figure 5B).³⁰

Figure 3 Homoplasmy of the m.15992A>T MT-TP mutation



(A) Strategy of the mispairing PCR for restriction analysis of the m.15992A>T mutation proportion. Italic characters indicate the primers used to amplify the 200-bp-long mtDNA fragment from position 15820 to 16019; Ddel restriction site is highlighted in cyan blue; the nucleotide position 15992 in underlined bold blue character; the mispairing position in the backward primer is in underlined bold red. (B) Restriction fragments of mtDNA fragments cut with Ddel. P1, P2, P3, P4, P5, and P6 = patients 1, 2, 3, 4, 5, and 6 respectively; C = wild-type controls; M = DNA from muscle, L = DNA from blood leukocytes DNA, U = DNA from urinary sediment; B = DNA from buccal cells; F = DNA from cultured skin fibroblasts. The need for mispairing is shown in the upper panel with the control sample (C) amplified with and without mispairing and then cut with Ddel. Without mispairing, the WT restriction fragment run only slightly above the mutated fragments, in agreement with their length being only 5 bp longer than the mutant fragments. With mispairing abolishing the Ddel site at position 15,996, all samples amplified from patients' tissues run homogeneously at a longer distance than wild-type control mtDNA fragment in agreement with their 28 bp shorter length. The upper panel also shows that the mutation appeared homoplasmic in every tissue tested in several members of family 1. The rest of the panels show that the mutation appeared homoplasmic in every member analyzed in the 2 families where DNA from blood leukocytes was available (figure 1). It also appeared homoplasmic in cultured fibroblasts derived from a skin biopsy of patients 1, 2, 3, and 4 and in the cybrid clones obtained from either patient 2 or patient 4 fibroblasts. mtDNA = mitochondrial DNA; WT = wild type.

The mutant tRNA^{Pro} had a lower steady-state but normal aminoacylation

Northern blot analysis in several cell lines revealed significant decrease of the amount of the mitochondrial tRNA^{Pro} in all the mutant cell lines, fibroblasts, or cybrids (figure e-2A, links.lww.com/NXG/A280). Cybrids also disclosed an increase of tRNA^{Val}, which could suggest an increase in the mitochondrial ribosomes because tRNA^{Val} is one of their integral components.³¹

In accordance, mitochondrial translation, studied in 2 patients' fibroblast lines by [³⁵S]-methionine pulse-chase incorporation, showed a moderately decreased translation of most mtDNA-encoded proteins (figure e-2B, links.lww.com/NXG/A280).


As expected, because the mutated base was not known as involved in the prolyl-tRNA synthetases recognition of the tRNA^{Pro}, the in vivo aminoacylation state of the mutant tRNA appeared as normal¹⁷ (figure e-3A, links.lww.com/NXG/A281).

Because tRNA^{Pro} is encoded in the light mtDNA strand, its sequence is in the reverse sense. Mutation m.15992A>T thus replaces the wild-type uridine in the tRNA sequence by an adenine at the wobble position of the anticodon. A nonmodified adenine in the wobble position of tRNA is very rare and is almost always deaminated into inosine to improve the decoding process.³² We investigated whether that was the case for the mutant mitochondrial tRNA^{Pro}, using the fact that inosine is read as guanosine during the RT-PCR reaction.¹⁹ In both fibroblasts and cybrids, we could not detect any trace of inosine in the mutant mitochondrial tRNA^{Pro} (figure e-3B, links.lww.com/NXG/A281). This result fitted with the absence of the needed enzymatic apparatus in mitochondria.³³

Abnormal decrease of the cell volume in mutant cybrids on depolarization by external potassium was reminiscent of the exercise-induced muscle edema observed in patients

Ionic disturbances were a striking observation in 2 families with the m.15992A>T mutation. They were reminiscent of ionic disturbances observed in patients with homoplasmic MT-ATP6 mutations and recurrent paralysis episodes associated with significant plasma membrane depolarization in fibroblasts.²² Core facilities providing patch-clamp electrophysiologic analyses are scarce. Therefore, to analyze the plasma membrane potential in cybrids, we used an indirect determination based on TMRE, a fluorescent probe that follows Nernst equation and thus may be used to analyze membrane potentials.³⁴ Because 7.5 μM TMRE significantly decreases respiration,³⁴ the mitochondrial membrane potential does not influence the TMRE fluorescence signal, which thus essentially represents both the cell size and plasma membrane potential. As expected, increasing in isotonic conditions the external K concentration from 5 to 10, 20, 30, 40, and 80 mM led to progressive decrease of TMRE fluorescent signal to 91 ± 9, 78 ± 12, 73 ± 7, 61 ± 9, and 38 ± 10% of its initial value, respectively (analysis of 33 independent cell populations, mutant and wild type grouped). At the basal state, the size (evaluated by the forward scatter) and the TMRE fluorescence (evaluated by the fluorescence area FLA) did not differ between wild-type and mutant cybrids with either the m.15992A>T mutation or the m.9185T>C mutation previously associated with permanent plasma membrane depolarization²² (figure 5, C and D). In contrast, at 80 mM external K concentration, both types of mutant cybrids had significantly decreased their size, whereas wild-type cybrids had maintained a size similar to the basal state (figure 5C). All 3 cybrid types had

Figure 4 Mitochondrial activities in cells with the m.15992A>T mutation



decreased their TMRE signal, in accordance with the induced decrease of plasma membrane potential, but mutant cybrids to a level significantly lower than wild-type cybrids.


Discussion

In this article, we demonstrate the pathogenicity of an original homoplasmic *MT-TP* mutation targeting skeletal muscle. In muscle, the severe combined respiratory chain defect demonstrated the mtDNA origin of the disease. However, we could not exclude a nuclear DNA alteration solely affecting muscle mtDNA expression because the absence of paternal transmission by the few affected fathers was insufficient to demonstrate maternal inheritance. Therefore,

we had to provide demonstration of the mutation deleterious potential.

As observed with other deleterious homoplasmic mtDNA mutations with restricted clinical expression, fibroblasts and cybrids presented with very mild enzymatic defect.^{6,35} However, that defect was statistically significant with unbiased nonparametric statistical tests. In addition, it induced significant reduction of the mutant cells proliferation in the absence of glucose showing its relevance to cell physiology.³⁶ Because most organs essentially comprise postmitotic cells, cell proliferation is not relevant for clinical symptoms. Therefore, we addressed the ionic disturbances that were a striking aspect of the disease, prominent in 2 families. When faced to an isotonic high potassium concentration, inducing plasma

Figure 5 Functional impact of the m.15992A>T mutation outside OXPHOS pathway



membrane depolarization, cybrids with the *MT-TP* mutation differed from wild-type cybrids by losing part of their cell volume, most probably through loss of internal fluid. That behavior fitted with the edema observed in patients using muscle imaging after 15-minute chewing effort.

At the molecular level, the mutant mitochondrial tRNA^{Pro} had a reduced steady-state level in cells. It bore an unmodified adenosine at the wobble position of its anticodon, which thus should optimally recognize only codon CCU that represents less than 25% of the total mtDNA proline codons. Special mitochondrial decoding rules probably allowed the mutant tRNA to recognize all the 4 proline codons, but less efficiently.

These 2 anomalies (reduced tRNA steady-state and decoding problems) might have a cumulative effect on mitochondrial translation. Why the impact on OXPHOS was mild in fibroblasts and cybrids but drastic in muscle remained hypothetical in the absence of appropriate muscle fragments.

The role of the J1c10 haplotype in the mutation pathophysiology was disputable. That haplotype was constant in the 5 families here reported and in the sole GenBank report of the mutation. It is not pathogenic in itself, being observed in 2.5%–5% of the people living in the western half of France, but it is a significant modifier in Leber hereditary optic neuropathy^{37,38} and in the cybrid resistance to rotenone toxicity.³⁹

According to the pathogenicity scoring system for tRNA mutations updated in 2011,⁷ mutation m.15992A>T has a score of 13, which indicated a mutation definitely pathogenic (2 for independent pedigrees, 2 for phylogenetic conservation, 2 for muscle histology, 2 for biochemical defects, and 5 for cybrid analysis).

The homoplasmic m.15992A>T *MT-TP* mutation in the J1c10 haplotype causes severe intolerance to exercise, often associated with exercise-induced muscle edema.

Acknowledgment

The authors thank Frédéric Bouillaud, INSERM U1016, for his insightful discussion of the data; Dr. Armelle Magot, Centre de Référence Maladies Neuromusculaires AOC Hôtel-Dieu, CHU Nantes, for providing the results of patient 6 muscle biopsy; and Rafael Boucher, Clément Vaz, and Caroline L'Hermitte-Stead, INSERM U1016, for their efficient technical help.

Study funding

No targeted funding reported.

Disclosure

A. Lombès and I. Tarassov are financially supported by INSERM and CNRS. A. Lombès received grants from the Fondation pour la Recherche Médicale (FRM) (grant DPM20121125550), the AFM Telethon, and the AMMi (Association contre les Maladies Mitochondriales). I. Tarassov received financial support from the University of Strasbourg, the LabEx MitoCross, and the Graduate School IMCBio (National Program PIA, Programme Investissement d'Avenir). Go to Neurology.org/NG for full disclosures.

Publication history

Received by *Neurology: Genetics* December 4, 2019. Accepted in final form June 2, 2020.

Appendix 1 Authors

Name	Location	Contribution
Karine Auré, MD, PhD	Department of Neurophysiology, Foch Hospital, Suresnes, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Guillemette Fayet, MD, PhD	Centre de Référence Maladies Neuromusculaires Hôtel-Dieu, CHU Nantes, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Ivan Chicherin, PhD	M.V. Lomonosov State University, Moscow, Russia	Acquisition of data and analysis of data
Benoît Rucheton, PharmD	Service de Biochimie Métabolique CHU Pitié-Salpêtrière, AP-HP, Paris, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Sandrine Filaut	Service de Biochimie Métabolique CHU Pitié-Salpêtrière, AP-HP, Paris, France	Acquisition of data and analysis of data

Appendix 1 (continued)

Name	Location	Contribution
Julie Eichler, MSc	CNRS UMR 7156 GMGM, University of Strasbourg, France	Acquisition of data and analysis of data
Anne-Marie Heckel	CNRS UMR 7156 GMGM, University of Strasbourg, France	Acquisition of data and analysis of data
Florence Caillon, MD	Service de Radiologie et Imagerie Médicale Hôtel-Dieu, CHU Nantes, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Yann Péréon, MD, PhD	Centre de Référence Maladies Neuromusculaires Hôtel-Dieu AOC, CHU Nantes, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Nina Entelis, PhD	CNRS UMR 7156 GMGM, University of Strasbourg, France	Acquisition of data; analysis of data; and drafted and revised the manuscript
Ivan Tarassov, PhD	CNRS UMR 7156 GMGM, University of Strasbourg, France	Designed and conceptualized the study; acquisition of data; analysis of data; and drafted and revised the manuscript
Anne Lombès, MD, PhD	InsERM U1016 Institut Cochin, INSERM, Paris, France	Designed and conceptualized the study; acquisition of data; analysis of data; and drafted and revised the manuscript

References

- Craven L, Alston CL, Taylor RW, Turnbull DM. Recent advances in mitochondrial disease. *Annu Rev Genomics Hum Genet* 2017;18:257–275.
- Shanske S, Moraes CT, Lombès A, et al. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. *Neurology* 1990;40:24–28.
- Carelli V, Giordano C, d'Amati G. Pathogenic expression of homoplasmic mtDNA mutations needs a complex nuclear-mitochondrial interaction. *Trends Genet* 2003;19:257–262.
- Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Science* 1988;242:1427–1430.
- Prezant TR, Agopian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. *Nat Genet* 1993;4:289–294.
- Taylor RW, Giordano C, Davidson MM, et al. A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2003;41:1786–1796.
- Yarham JW, Al-Dosary M, Blakely EL, et al. A comparative analysis approach to determining the pathogenicity of mitochondrial tRNA mutations. *Hum Mutat* 2011;32:1319–1325.
- King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. *Science* 1989;246:500–503.
- Jun AS, Trounce IA, Brown MD, Shoffner JM, Wallace DC. Use of trans-mitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes leber hereditary optic neuropathy and dystonia. *Mol Cell Biol* 1996;16:771–777.
- Toompuu M, Tiranti V, Zeviani M, Jacobs HT. Molecular phenotype of the np 7472 deafness-associated mitochondrial mutation in osteosarcoma cell cybrids. *Hum Mol Genet* 1999;8:2275–2283.
- Fender A, Sissler M, Florentz C, Giege R. Functional idiosyncrasies of tRNA isoacceptors in cognate and noncognate aminoacylation systems. *Biochimie* 2004;86:21–29.
- Watanabe K. Unique features of animal mitochondrial translation systems. The non-universal genetic code, unusual features of the translational apparatus and their relevance to human mitochondrial diseases. *Proc Jpn Acad Ser B Phys Biol Sci* 2010;86:11–39.

13. Hogrel JY, Laforêt P, Ben Yaou R, Chevrot M, Eymard B, Lombès A. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. *Neurology* 2001;56:1733–1738.
14. Dubowitz V, Sewry CA, Oldfors A. *Muscle Biopsy: A Practical Approach*. Philadelphia, PA: Saunders Elsevier; 2013.
15. Possekel S, Lombès A, Ogier de Baulny H, et al. Immunohistochemical analysis of muscle cytochrome c oxidase deficiency in children. *Histochem* 1995;103:59–68.
16. Agier V, Oliviero P, Lainé J, et al. Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations. *Biochim Biophys Acta* 2012;1822:1570–1580.
17. Varshney U, Lee CP, RajBhandary UL. Direct analysis of aminoacylation levels of tRNAs in vivo. Application to studying recognition of *Escherichia coli* initiator tRNA mutants by glutamyl-tRNA synthetase. *J Biol Chem* 1991;266:24712–24718.
18. Karicheva OZ, Kolesnikova OA, Schirtz T, et al. Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. *Nucleic Acids Res* 2011;39:8173–8186.
19. Kawahara Y. Quantification of adenosine-to-inosine editing of microRNAs using a conventional method. *Nat Protoc* 2012;7:1426–1437.
20. Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. *Methods Mol Biol* 2012;810:25–58.
21. Medja F, Allouche S, Frachon P, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. *Mitochondrion* 2009;9:331–339.
22. Auré K, Dubourg O, Jardel C, et al. Episodic weakness due to mitochondrial DNA MT-ATP6/8 mutations. *Neurology* 2013;81:1810–1818.
23. Haraux F, Lombès A. Kinetic analysis of ATP hydrolysis by complex V in four murine tissues: towards an assay suitable for clinical diagnosis. *PLoS One* 2019;14:e0221886.
24. Auré K, Fayet G, Leroy JP, Lacène E, Romero NB, Lombès A. Apoptosis in mitochondrial myopathies is linked to mitochondrial proliferation. *Brain* 2006;129:1249–1259.
25. Auré K, Mamchaoui K, Frachon P, Butler-Brown GS, Lombès A, Mouly V. Impact on oxidative phosphorylation of immortalization with the telomerase gene. *Neuromuscul Disord* 2007;17:368–375.
26. Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. *Nat Protoc* 2008;3:1125–1131.
27. Yasukawa T, Suzuki T, Ishii N, Ohta S, Watanabe K. Wobble modification defect in tRNA disturbs codon-anticodon interaction in a mitochondrial disease. *EMBO J* 2001;20:4794–4802.
28. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. *J Biol Chem* 1979;254:2669–2676.
29. Will Y, Dykens J. Mitochondrial toxicity assessment in industry—a decade of technology development and insight. *Expert Opin Drug Metab Toxicol* 2014;10:1061–1067.
30. Quinlan CL, Gerencser AA, Treberg JR, Brand MD. The mechanism of superoxide production by the antimycin-inhibited mitochondrial Q-cycle. *J Biol Chem* 2011;286:31361–31372.
31. Rorbach J, Gao F, Powell CA, et al. Human mitochondrial ribosomes can switch their structural RNA composition. *Proc Natl Acad Sci U S A* 2016;113:12198–12201.
32. Grosjean H, de Crecy-Lagard V, Marck C. Deciphering synonymous codons in the three domains of life: co-evolution with specific tRNA modification enzymes. *FEBS Lett* 2010;584:252–264.
33. de Crecy-Lagard V, Boccaletto P, Mangleburg CG, et al. Matching tRNA modifications in humans to their known and predicted enzymes. *Nucleic Acids Res* 2019;47:2143–2159.
34. Scaduto RC Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. *Biophys J* 1999;76:469–477.
35. Howell N. Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve? *J Bioenerg Biomembr* 1997;29:165–173.
36. Rossignol R, Letellier T, Malgat M, Rocher C, Mazat JP. Tissue variation in the control of oxidative phosphorylation: implication for mitochondrial diseases. *Biochem J* 2000;347(pt 1):45–53.
37. Carelli V, Achilli A, Valentino ML, et al. Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. *Am J Hum Genet* 2006;78:564–574.
38. Hudson G, Carelli V, Spruijt L, et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. *Am J Hum Genet* 2007;81:228–233.
39. Strobe D, Caporali L, Iommarini L, et al. Haplogroup J mitogenomes are the most sensitive to the pesticide rotenone: relevance for human diseases. *Neurobiol Dis* 2018;114:129–139.